Pituitary gland

Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Woman, Committee, Acne, Monograph, Headache, Chronic pain, Breast, Hypothalamus, Dizziness, Nausea, Date, Mouth, Urinary system, Safety, Stomach, Premenstrual syndrome, Pituitary gland, Allergy, Rash, Patient, Fruit, Medicine, DSM-IV codes, Herbal medicine, Irritability, Ethanol, Brain, Dietary supplement

Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Pharmactive's Saffron Extract improves Resilience to Occasional Stress

Retrieved on: 
Wednesday, January 24, 2024
DSM-IV codes, Hypothalamus, Arginine, Iterative method, Pituitary gland, Research, Overalls, Manager, Food, Health, Brain-derived neurotrophic factor, HPA, Hormone, Survival, Communication, History, Nutrient, Anxiety, Pandemic, Human, Gland, Doctor of Philosophy, Rat, Anhedonia, ACTH, Adrenocorticotropic hormone, CRF, Brain, Motivation, Glucocorticoid, BDNF, Depression, Growth

MADRID, Jan. 24, 2024 /PRNewswire/ -- A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.

Key Points: 
  • The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.
  • Results demonstrated significant improvements following repeated oral administration of the extract in stress model animal subjects.
  • The HPA axis is a vital brain signaling system involved in orchestrating responses to stress.
  • We are realizing these extend beyond influencing serotonin expression but actually demonstrates a potential to boost resilience to occasional stress and prevent its detrimental impact on overall mental and physical health."

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023
Sale, Peptide, Infant, Abdominal pain, Headache, Triptorelin, Patient, Oxytocin, Ovulation, Water intoxication, Pharyngitis, Infection, Oxygen, Background, Amniotic fluid, Erectile dysfunction, Lethargy, Pharmacy, Vomiting, Placenta, Osteoporosis, Safety, Fertility, Argyreia nervosa, Asphyxia, Canada Border Services Agency, DIN, Pelvimetry, Uterine rupture, Nursing, Drug identification number, Toxemia, Health, Diarrhea, Bleeding, Health Canada, Nausea, Chronic pain, Plasma protein binding, Fetus, Allergy, Somnolence, Anaphylaxis, Endometriosis, Depression, Hormone, Risk, Constipation, History, Premature, Long QT syndrome, Stroke, Seizure, Pain, Natural product, Drug, Upper respiratory tract infection, NPN, Prostate cancer, Prescription drug, Pituitary gland, Dietary supplement

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

Retrieved on: 
Monday, July 31, 2023
KOL, MGH, Metabolism, Pituitary gland, Sequoyah, Clinical trial, Saint Andrew's Society, Medicine, Research, BSN, Harvard Medical School, Acromegaly, American Association of Clinical Endocrinologists, Patient, SAN, European Society of Endocrinology, Endocrine Society, Diagnosis, Hospital, Massachusetts General Hospital, Pharmaceutical industry, Adult, Endocrinology

(Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D.

Key Points: 
  • (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D.
  • and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs).
  • Karen JP Liebert, R.N., B.S.N., is a research nurse / study coordinator in the Neuroendocrine Department at Massachusetts General Hospital (MGH).
  • She is a member of the Endocrine Nursing Society and has co-authored numerous peer-reviewed publications.

Insights Revealed in 2023 Turner Syndrome Pipeline Report: 4+ Companies and 4+ Promising Drugs in Focus - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023
Genetics, Pharmaceutical, Health, Drug development, Therapy, Turner syndrome, Pituitary gland, Research, GH, Endocrine gland, X chromosome, Growth hormone, Chromosome, Patient, Southern Transcon, Ibutamoren, Pharmaceutical industry

This report presents comprehensive insights into the Turner Syndrome pipeline landscape, featuring 4+ companies and 4+ pipeline drugs.

Key Points: 
  • This report presents comprehensive insights into the Turner Syndrome pipeline landscape, featuring 4+ companies and 4+ pipeline drugs.
  • Turner Syndrome, also known as congenital ovarian hypoplasia syndrome, is the most common sex chromosomal abnormality found in females.
  • In most cases, Turner Syndrome is not inherited and results from a random event during the formation of reproductive cells.
  • Apart from Lumos Pharma and Ascendis Pharma, the report covers other companies actively engaged in developing therapies for Turner Syndrome.

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Retrieved on: 
Wednesday, June 28, 2023
Research, FDA, Children, Biotechnology, Health, Consumer, Pharmaceutical, Other Science, Science, GHD, Inc., EU, Pituitary gland, Growth hormone, PFE, Medicine, Puberty, OPKO Health, Patient, Standard of care, Ageing, Hybrid growth disorders, United, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, NYSE, Food, Disease, Pharmaceutical industry, Birth control, Pfizer

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
  • The study met its primary endpoint of NGENLA non-inferiority compared to somatropin, as measured by annual height velocity at 12 months.
  • “The approval of NGENLA will be significant for children with growth hormone deficiency in the U.S.
  • It holds potential to reduce the treatment burden that can come with daily growth hormone injections,” said Joel Steelman, M.D., Pediatric Endocrinologist, Cook Children’s Health Care System.

Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk

Retrieved on: 
Wednesday, March 8, 2023
History, Mortality, Phase 3, Circulatory system, CMO, Follicle-stimulating hormone, Prostate cancer, Cardiovascular disease, Death, Standard of care, Cancer, ADT, CVD, FDA, Principal Scientific Adviser to the Government of India, Hormone, Breast, Bray, Pituitary gland, Patient, Disease, GenesisCare, Follicle, Prostate, Treatment, MACE, Personalized medicine, American Heart Association, Testosterone, Incidence, Prevalence, Androgen deprivation therapy, Luteinizing hormone, Gonadotropin-releasing hormone, US Foods, Risk, Pharmaceutical industry, Medical imaging, Birth control, Ernst Antevs

Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease.

Key Points: 
  • Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease.
  • This would be the first Phase 3 trial for a specific label to treat prostate cancer in patients with increased cardiovascular risk, addressing a significant need for prostate cancer drugs with a better cardiac toxicity profile.
  • Teverelix, a decapeptide, has the potential to be the first hormone therapy specifically approved to treat advanced prostate cancer patients with a history of cardiovascular disease.
  • “We are delighted to reach this critical milestone in Antev’s journey to secure regulatory guidance to develop Teverelix in advanced prostate cancer patients with increased cardiovascular risk,” commented Amit Kohli, Chief Executive Officer of Antev.

Global Fertility Services Market Report 2022 to 2027: Players Include Instituto Bernabeu, INVO Bioscience, Monash IVF and Apollo Hospitals Enterprise - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 22, 2023
Health, Other Health, Pituitary gland, IVF, Meigs's syndrome, Family, Causality, Fertility, PCOS, LGBT, Pregnancy, Brain, Workload, ART, Cryopreservation, Growth, Advertising, Assisted reproductive technology, Vertically transmitted infection, Hypothalamus, Smoking, COVID-19, Prevalence, Birth control, Infertility

Fertility services refer to the procedures provided as a treatment for infertility.

Key Points: 
  • Fertility services refer to the procedures provided as a treatment for infertility.
  • Among males, it is identified by a low sperm count or is a result of hormonal imbalance in men.
  • They involve fertility drugs, artificial insemination, In Vitro Fertilization (IVF), egg-freezing or oocyte cryopreservation, surrogacy, Assisted Reproductive Technology (ART) procedures, etc.
  • The publisher provides an analysis of the key trends in each sub-segment of the global fertility services market report, along with forecasts at the global and regional level from 2022-2027.

Brain Tumor Fighter Finds Comfort and Community in Rocky Mountain Fisher House

Retrieved on: 
Tuesday, January 17, 2023
Memory, Transport, Fisher, News, Fisher House, Pituitary gland, Fisher House Foundation, Parent, Reunion, Mekong Delta, VA, Pressure, Friends, Hotel, Surgeon, Thought, Neoplasm, Woman, Spouse, Radiation, Cancer, House Foundation, Cyst, Multimedia, Medical imaging, Health insurance, Hospital, Dentistry

"He says, 'Everything is just fine and dandy, except you have a brain tumor.'

Key Points: 
  • "He says, 'Everything is just fine and dandy, except you have a brain tumor.'
  • A patient advocate let her know that, because of her husband's service, she would be eligible to stay at the Rocky Mountain Regional Fisher House.
  • Between her new friends at the Fisher House and her husband, Eugenia had a full support group as she went through radiation.
  • "We both feel blessed to have the Fisher House just two-and-a-half hours from our home," the couple said.

World’s Tallest Man Celebrates 40th Birthday with Visit to Ripley’s Believe It or Not!

Retrieved on: 
Thursday, December 8, 2022
Growth hormone, Pituitary gland, Neoplasm, History, Wrist, Death, Guinness World Records

ORLANDO, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- A towering 8 feet 3 inches tall, world’s tallest man Sultan Kösen celebrated a milestone — his 40th birthday — at Ripley’s Believe It or Not!

Key Points: 
  • ORLANDO, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- A towering 8 feet 3 inches tall, world’s tallest man Sultan Kösen celebrated a milestone — his 40th birthday — at Ripley’s Believe It or Not!
  • At Ripley’s, Sultan stopped to pose next to the tallest man to have ever lived, Robert Wadlow, of Alton, Illinois.
  • Believe It or Not!, there are only ten reliable cases in history of a person reaching 8 feet or more.
  • “After that day [that I was announced the tallest man in the world] I was born,” Sultan explained to Ripley’s.